Home Tags Takeda: Millennium

Tag: Takeda: Millennium

Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin lymphoma: Study...

The final data of the brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda Oncology) monotherapy pivotal phase II clinical trial in relapsed or refractory (R/R) classical Hodgkin...

Takeda and ImmunoGen Sign Licensing Agreement

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (Osaka, Japan), and ImmunoGen, Inc. a biotechnology company that develops targeted anticancer therapeutics using its...

ADC Market to Reach US$ 3 Billion by 2018

According to a report published by Research & Markets, one of the world's largest and most respected market research resource, the global market for Antibody-drug...

X